NBIX

Business Context and Reporting Period

Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: Neurocrine is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for neurological and endocrine-related diseases. The company has no approved products and generates revenue primarily through strategic collaborations and research agreements. Its lead clinical candidate is indiplon, a non-benzodiazepine GABA-A receptor agonist for the treatment of insomnia, currently in Phase III trials in collaboration with Pfizer.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: Total revenues increased by $121.1 million (671%) from 2002 to 2003. This was driven primarily by the Pfizer collaboration, which contributed $128.9 million in revenue (comprising $90.9 million in sponsored development reimbursements and $38.0 million in amortized upfront fees).
• Reduced Net Loss: Net loss decreased significantly from $94.5 million in 2002 to $30.3 million in 2003. This improvement was due to the revenue increase from Pfizer and a one-time gain of approximately $18.0 million from the sale of the company's corporate headquarters, partially offset by higher R&D expenses.
• Increased R&D Spend: Research and development expenses rose by $68.3 million to $177.3 million, reflecting the advancement of the indiplon Phase III program and expanded clinical trial enrollment.
• Liquidity Position: Cash and short-term investments grew by $208.5 million to $453.2 million, fueled by a $100 million upfront payment from Pfizer and net proceeds of $187.4 million from a September 2003 public stock offering.

Guidance, Outlook, and Risks

• Indiplon Timeline: Management anticipates filing a New Drug Application (NDA) for indiplon in mid-2004. Upon FDA approval (expected in 2005), the company expects to begin receiving royalties and milestone payments.
• Profitability Outlook: The company expects to incur a net loss in 2004 but anticipates crossing over into profitability during 2005, driven by indiplon commercialization and milestone achievements.
• Sales Force: Following the NDA filing, Pfizer will fund the creation of a 200-person Neurocrine sales force to co-promote indiplon and Pfizer's Zoloft in the U.S.
• Key Risks:
  • Clinical Failure: Failure of Phase III trials for indiplon would severely harm the business, as it is the most advanced program.
  • Collaboration Dependence: Heavy reliance on Pfizer for funding and commercialization; Pfizer may terminate the agreement with 180 days' notice.
  • Regulatory Approval: No products are currently approved; delays or rejections by the FDA would prevent revenue generation from product sales.
  • Intellectual Property: Risks regarding patent infringement claims and the ability to protect proprietary technology.

Investor Verification Checklist

• Indiplon Phase III Data: Verify the final results of the remaining Phase III clinical trials and the specific timeline for the NDA filing in mid-2004.
• Pfizer Collaboration Terms: Confirm the specific milestones triggering the remaining $300 million in potential payments and the conditions for the $175 million credit facility.
• Wyeth/DOV Transaction: Monitor the closing of the $95 million transaction (scheduled for March 15, 2004) to acquire Wyeth's financial interest in indiplon, which reduces Neurocrine's royalty obligation from 6% to 3.5%.
• Cash Burn Rate: Assess whether the $453 million cash balance is sufficient to fund operations through 2005 without additional dilutive financing, considering the construction costs for the new headquarters.
• Legal Proceedings: Review the status of the arbitration demand filed by The Salk Institute regarding milestone payments for CRF antagonists.